Clinical trial
"Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"
NCT04826692 is registered in ClinicalTrials.gov with Instituto de Investigacion Sanitaria La Fe as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"
- Lead sponsor
- Instituto de Investigacion Sanitaria La Fe
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 11, 2022
- Completion date
- June 10, 2025
- Enrollment
- 60 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.